REPUBLIC OF TURKEY
MINISTRY OF HEALTH
TURKISH MEDICINES AND MEDICAL DEVICES AGENCY
Certificate of a Pharmaceutical Product[1]

25/11/2019

(This certificate conforms to the format recommended by the World Health Organization (see instructions and explanatory notes attached)

Certificate No : 2019/3672

Exporting Country : Turkey
Importing Country : Republic of North Macedonia

1. Name and dosage form of product :
DOBCARD 250 MG/20 ML I.V. CONCENTRATE FOR SOLUTION FOR INFUSION AMPOULE

1.1. Active ingredient(s)[2] and amount(s) per unit dose :[3] :
It contains 14 mg dobutamine hydrochloride that is equivalent to 12.5 mg dobutamine per ml. Each ampoule of 20 ml contains 280 mg dobutamine hydrochloride that is equivalent to 250 mg dobutamine.
The formula (complete composition) attached/For complete qualitative composition including excipients[4]

1.2. Is this product licensed to be placed on the market for use in the exporting country?[5]
YES

1.3. Is this product actually on the market in the exporting country ? YES
If the answer to 1.2. is yes, continue with section 2A and omit section 2B.
If the answer to 1.2. is no, omit section 2A and continue with section 2B.[6]

2A.1. Number of product licence[7] and date of issue :
216/93-17 September 2008

2A.2. Product-licence holder (name and address) :
VEM İlaç San. ve Tic. A.Ş.
Söğütözü Mahallesi 2177.Cad. No: 10 B/49
Çankaya, Ankara/TURKEY
Factory address:
Çerkezköy Organize Sanayi Bölgesi
Karaağaç Mahallesi Fatih Bulvarı No:38
Kapaklı/TEKİRDAĞ/TURKEY

2A.3. Status of product-licence holder :[8] a/b/c *(key in appropriate category as defined in note 8)* **A**

2A3.1. For categories b and c the name and address of the manufacturer producing the dosage form are :[9]
(Key in appropriate category as defined in note 8)

2A.4. Is Summary Basis of Approval appended ?[10]
NO

2A.5. Is the attached, officially approved product information complete and consonant with the licence ?[11]
Not Provided

2A.6. Applicant for certificate, if different from licence holder (name and address) :[12] ----------

This certificate is valid until ...25.11.2021

Address and certifying authority:
REPUBLIC OF TURKEY
TURKISH MEDICINES AND MEDICAL DEVICES AGENCY
Söğütözü Mahallesi 2176 Sokak No: 5 06520 Çankaya/Ankara/Turkey
Facsimile: +90 312 218 34 60 Phone: +90 312 218 30 00

2B.1 Applicant for certificate *(name and address)* :

2B.2 Status of applicant : a/b/c *(key in appropriate category as defined in note 8)*

2B.2.1 For categories b and c the name and address of the manufacturer producing the dosage form are :[9]

2B.3 Why is marketing authorization lacking ?
Not required/not requested/under consideration/refused (key in as appropriate)

2B.4 Remarks :[13]
----

3. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced ? yes/no/not applicable[14]
YES

3.1 Periodicity of routine inspections (years) :
3 YEARS

3.2 Has the manufacture of this type of dosage form been inspected ?
YES

3.3 Do the facilities and operations conform to GMP as recommended by the World Health Organization)[15]
YES

4. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product ?[16] yes/no *(key in as appropriate) : YES*
If no, explain : _____

S.R.L. medeferent grup IDNO 1002600053

Name of Authorized Person

Fatmagül ÖZTUNCA Pharm.M.Sc.
Head of Herbal and Supportive Medicines Department

General instructions

Please refer to the guidelines for full instructions on how to complete this form and information on the implementation of the Scheme.

The forms are suitable for generation by computer. They should always be submitted as hard copy, with responses printed in type rather than handwritten.

Additional sheets should be appended, as necessary, to accommodate remarks and explanations

Explanatory notes

1. This certificate, which is in the format recommended by WHO, establishes the status of the pharmaceutical product and of the applicant for the certificate in the exporting country. It is for a single product only since manufacturing arrangements and approved information for different dosage forms and different strengths can vary.

2. Use, whenever possible, International Nonproprietary Names (INNs) or national nonproprietary names.

3. The formula (complete composition) of the dosage form should be given on the certificate or be appended.

4. Details of quantitative composition are preferred, but their provision is subject to the agreement of the product-licence holder.

5. When applicable, append details of any restriction applied to the sale, distribution or administration of the product that is specified in the product licence.

6. Sections 2A and 2B are mutually exclusive.

7. Indicate, when applicable, if the licence is provisional, or the product has not yet been approved.

8. Specify whether the person responsible for placing the product on the market:

   (a) manufactures the dosage form;
   (b) packages and/or labels a dosage form manufactured by an independent company; or
   (c) is involved in none of the above.

9. This information can be provided only with the consent of the product-licence holder or, in the case of non-registered products, the applicant. Non-completion of this section indicates that the party concerned has not agreed to inclusion of this information.

   It should be noted that information concerning the site of production is part of the product licence. If the production site is changed, the licence must be updated or it will cease to be valid.

10. This refers to the document, prepared by some national regulatory authorities, that summarizes the technical basis on which the product has been licensed.

11. This refers to product information approved by the competent national regulatory authority, such as a Summary of Product Characteristics (SPC).

12. In this circumstance, permission for issuing the certificate is required from the product-licence holder. This permission must be provided to the authority by the applicant.

13. Please indicate the reason that the applicant has provided for not requesting registration:

    (a) the product has been developed exclusively for the treatment of conditions .particularly tropical diseases— not endemic in the country of export;
    (b) the product has been reformulated with a view to improving its stability under tropical conditions;
    (c) the product has been reformulated to exclude excipients not approved for use in pharmaceutical products in the country of import:
    (d) the product has been reformulated to meet a different maximum dosage limit for an active ingredient;
    (e) any other reason, please specify.

14. Not applicable means that the manufacture is taking place in a country other than that issuing the product certificate and inspection is conducted under the aegis of the country of manufacture.

15. The requirements for good practices in the manufacture and quality control of drugs referred to in the certificate are those included in the thirty-second report of the Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 823, 1992, Annex 1). Recommendations specifically applicable to biological products have been formulated by the WHO Expert Committee on Biological Standardization (WHO Technical Report Series, No. 822, 1992, Annex 1).

16. This section is to be completed when the product-licence holder or applicant conforms to status (b) or (c) as described in note 7 above. It is of particular importance when foreign contractors are involved in the manufacture of the product. In these circumstances the applicant should supply the certifying authority with information to identify the contracting parties responsible for each stage of manufacture of the finished dosage form, and the extent and nature of any controls exercised over each of these parties.

UNIT FORMULA

Name of the product: DOBCARD 250mg/20ml I.V. Concentrate for Solution for Infusion Ampoule

Pharmaceutical form: Concentrate solution for infusion.

Composition:

	Quantity	Function	Reference
Active Substance			
Dobutamine hydrochloride	14 mg/ml (equilavent to 12.5 mg dobutamine base)	Inotropic agent	EP
Excipients			
Sodium metabisulfite	0.24 mg	Preservative	EP
NaOH or HCl	q.s for pH 2.5-5.5	pH adjustment	EP
Water for injection	q.s for 1 ml	Solvent	EP

Property of package: Colorless, type I glass ampoule containing 20 ml solution.

Packaging: 10 x 20 ml ampoule/box

Tufan ŞAHAN
Responsible Manager

VEM İLAÇ SANAYİ VE TİCARET ANONİM ŞİRKETİ
Söğütözü Mah. 2177. Cd. No: 10 B/49 Çankaya / ANKARA
Tel: (0.312) 427 43 57-58 Fax: (0.312) 427 43 59
Mersis No: 0324 049 3027

REPUBLIKA HRVATSKA
AGENCIJA ZA LIJEKOVE I MEDICINSKE PROIZVODE

REPUBLIC OF CROATIA
AGENCY FOR MEDICINAL PRODUCTS AND MEDICAL DEVICES
Ksaverska c 4, 10000 ZAGREB, CROATIA
Tel.: ++ 385 1 4884 100, Fax: ++385 1 4884 110
e-mail: halmed@halmed.hr
www.halmed hr
OIB 37926884937

Klasa: UP/I-530-10/20-03/08
Ur.broj: 381-13-08/162-20-03

POTVRDA O PROVOĐENJU DOBRE PROIZVOĐAČKE PRAKSE[1,2]
CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER[1,2]

DIO 1
Part 1

Nakon provedenog nadzora u skladu sa člankom 111(5) Direktive 2001/83/EZ Europskog parlamenta i Vijeća.
Issued following an inspection in accordance with Art. 111(5) of Directive 2001/83/EC.

Nadležno tijelo Republike Hrvatske potvrđuje sljedeće:
The competent authority of Croatia confirms the following:

Proizvođač: **Vem Ilac Sanayi ve Ticaret A.S.**
*The manufacturer: **Vem Ilac Sanayi ve Ticaret A.S.***

Mjesto proizvodnje: **Çerkezköy Organize Sanayi Bölgesi Karaağaç Mah. Fatih Bulvari No:38 Kapaklı-TEKİRDAĞ 59510, Turska**
*Site address: **Çerkezköy Organize Sanayi Bölgesi Karaağaç Mah. Fatih Bulvari No:38 Kapaklı-TEKİRDAĞ 59510, Turkey***

Proveden je nadzor proizvođača izvan Europskog gospodarskog prostora, a koji se navodi u dokumentaciji odobrenja za stavljanje lijeka u promet, u skladu s člankom 111(4) Direktive 2001/83/EZ transponiranim u nacionalnom zakonodavstvu, članak 40. Zakona o lijekovima („Narodne novine“, broj 76/13., 90/14. i 100/18.).
Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Art. 111(4) of Directive 2001/83/EC transposed in the following national legislation Art. 40 Medicinal Products Act (Official Gazette No. 76/13, 90/14 and 100/18).

Provedenim inspekcijskim nadzorom proizvođača, od kojih je posljednji proveden dana 14. listopada 2019. godine utvrđeno je da proizvođač udovoljava zahtjevima dobre proizvođačke prakse sukladno principima i smjernicama dobre proizvođačke prakse propisanim Direktivom 2003/94/EZ[3].
From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 14/10/2019, it is considered that it complies with the Good Manufacturing Practice requirements referred to in The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC[3].

Ova potvrda odnosi se na stanje mjesta proizvodnje u trenutku provedbe gore navedenog nadzora, i ne treba se smatrati da odražava stvarno stanje usklađenosti ukoliko su prošle više od tri godine od datuma nadzora. Međutim, rok važenja potvrde može se skratiti ili produljiti na temelju principa primijenjenog upravljanja rizicima inspekcije Agencije, na način da se isto unese u polje Ograničenja i pojašnjenja.
This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field.

Ova potvrda vrijedi isključivo ukoliko sadrži sve stranice, kao i DIO 1 i dijela DIO 2.

DIO 2
Part 2

☒ **Lijekovi Human** ***Medicinal Products***	
1. PROIZVODNJA ***1. MANUFACTURING OPERATIONS – MEDICINAL PRODUCTS***	
1.1.	**Sterilni lijekovi** ***Sterile products***
	1.1.1. Aseptički pripravljeni lijekovi *Aseptically prepared* 1.1.1.4. Tekućine malih volumena *Small volume liquids* 1.1.1.6. Ostali aseptički pripravljeni oblici: *Other aseptically prepared products:* Prašak za otopinu za injekciju ili infuziju *Powder for solution for injection or infusion*
1.5.	**Opremanje** ***Packaging***
	1.5.2. Vanjsko pakiranje *Secondary packing*
1.6.	**Provjera kakvoće** ***Quality control testing***
	1.6.1. Mikrobiološko ispitivanje: sterilnost *Microbiological: sterility*
	1.6.2. Mikrobiološko ispitivanje: mikrobiološka čistoća *Microbiological: non-sterility*
	1.6.3. Kemijska/fizička ispitivanja *Chemical/Physical*

Ograničenje ili pojašnjenje vezano za navedeno u ovoj potvrdi:
Any restrictions or clarifying remarks related to the scope of this certificate:

Opseg ove potvrde o provođenju dobre proizvođačke prakse se odnosi na proizvodnu liniju Ampoule-1 line i Sterile Powder Line.
Scope of this GMP certificate is refering to manufacturing lines Ampoule-1 line and Sterile Powder Line.

Datum: 20.04.2020.
Date: 20/04/2020

Ime, prezime i potpis ovlaštene osobe
nadležnog tijela Republike Hrvatske
Name and signature of the authorised person
of the Competent Authority of Croatia

Inspektor Agencije
Inspector

Saša Polović, MChem

Agencija za lijekove i medicinske proizvode
Agency for Medicinal Products and Medical Devices
of Croatia

Dragomir Budimir, LLM

REPUBLIKA HRVATSKA - AGENCIJA ZA LIJEKOVE I MEDICINSKE PROIZVODE ZAGREB

This certificate is valid only when presented with all pages and both Parts 1 and 2.

Autentičnost ove potvrde može se provjeriti u EudraGMDP bazi podataka. Ako nije dostupna u EudraGMDP bazi, obratite se tijelu koje je izdalo potvrdu.

The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

[1] GMP potvrda iz članka 111(5) Direktive 2001/83/EC primjenjuje se i za uvoznike.
The certificate referred to in paragraph 111(5) of Directive 2001/83/EC is also applicable to importers.

[2] Pojašnjenje ovog obrasca nalazi se u „Help menu" EudraGMDP baze
Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database

[3] Ovi zahtjevi ispunjavaju preporučene zahtjeve WHO za DPP
These requirements fulfil the GMP recommendations of WHO